Nutriband (NASDAQ:NTRB) versus Novo Nordisk A/S (NYSE:NVO) Head-To-Head Comparison

Novo Nordisk A/S (NYSE:NVO) and Nutriband (NASDAQ:NTRB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Novo Nordisk A/S and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80 billion	4.26	$15.51 billion	$4.09	10.91
Nutriband	$2.04 million	34.57	-$8.23 million	($0.53)	-10.94

Novo Nordisk A/S has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Novo Nordisk A/S has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Novo Nordisk A/S and Nutriband, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1	14	4	0	2.16
Nutriband	1	1	0	0	1.50

Novo Nordisk A/S presently has a consensus price target of $64.94, suggesting a potential upside of 45.53%. Given Novo Nordisk A/S’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Nutriband.

Profitability

This table compares Novo Nordisk A/S and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Nutriband	-430.35%	-109.07%	-95.54%

Institutional & Insider Ownership

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Nutriband on 10 of the 14 factors compared between the two stocks.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.